Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptus PharmaBOM:544529 +3.63%18 EBITDA Margin % is 14.33% as of Mar. 2026, which is 16% above its 10-year median of 12.32. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, Aptus Pharma ranks better than 89.92% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aptus Pharma's EBITDA for the
six
months ended in Mar. 2026 was ₹46.2 Mil. Aptus Pharma's Revenue for the
six
months ended in Mar. 2026 was ₹322.0 Mil. Therefore, Aptus Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 14.33%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aptus Pharma EBITDA Margin % Related Terms
Aptus Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Aptus Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544529 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Aptus Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptus Pharma EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Aptus Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aptus Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptus Pharma (BOM:544529) has a EBITDA Margin % of 14.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aptus Pharma and its competitors. This is 16% above median its historical median of 12.32. Over the past decade, Aptus Pharma's EBITDA Margin % has ranged from 4.13 to 20.06. According to the industry distribution chart, Aptus Pharma ranks #12 out of 119 companies in the Medical Distribution industry, placing it in the top 10.1%.
Is Aptus Pharma's EBITDA Margin % too high?
Aptus Pharma's current EBITDA Margin % of 14.33% is 16% above median its 10-year median of 12.32. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 20.06. The Medical Distribution industry median EBITDA Margin % is 4.11. Aptus Pharma's value of 14.33% is 248.7% above this industry median. Based on the distribution chart, Aptus Pharma ranks #12 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Aptus Pharma ranks #12 out of 119 companies for EBITDA Margin %. This places Aptus Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.11. Aptus Pharma's value of 14.33% is 248.7% above this benchmark. Historically, Aptus Pharma's own EBITDA Margin % has ranged from 4.13 to 20.06 over the past decade. While the company's 10-year median is 12.32 vs. the industry median of 4.11, Aptus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.11, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptus Pharma's current EBITDA Margin % of 14.33% is 248.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aptus Pharma and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current EBITDA Margin % is 14.33%, which is 16% above median its own 10-year median of 12.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current EBITDA Margin % of 14.33%. The current EBITDA Margin % is 14.33%, which is 16% above median its 10-year median of 12.32 and 248.7% above the Medical Distribution industry median of 4.11. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current EBITDA Margin % is 14.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score
Get the complete analysis for BOM:544529
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544529 has been successfully added to your 
